KKR dragged into another Bill Ackman drama
Plus, pharma dealmakers make a comeback in San Francisco confab and private equity ‘whitelists’ challenged
Plus, pharma dealmakers make a comeback in San Francisco confab and private equity ‘whitelists’ challenged